Why Drug Price Negotiation Has Staying Power
In this Axios column, Drew Altman looks beyond Medicare to what’s at stake for employers and workers in the debate about the government negotiating drug prices.
The independent source for health policy research, polling, and news.
KFF’s policy research provides facts and analysis on a wide range of policy issues and public programs.
KFF designs, conducts and analyzes original public opinion and survey research on Americans’ attitudes, knowledge, and experiences with the health care system to help amplify the public’s voice in major national debates.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the organization’s core operating programs.
In this Axios column, Drew Altman looks beyond Medicare to what’s at stake for employers and workers in the debate about the government negotiating drug prices.
Attention to high list prices continues at both the state and federal levels with a number of policy proposals aimed at lowering drug prices and there is renewed interest in drug prices and reimbursement within Medicaid. Changes made in 2016 to federal rules governing how state Medicaid programs pay for drugs aimed to make the prices paid more accurate, but increased reliance on pharmacy benefit managers (PBMs) pose challenges to drug price transparency. This brief explains Medicaid prescription drug prices to help policymakers and others understand Medicaid’s role in drug pricing and any potential consequences of policy changes for the program.
This infographic examines public opinion on surprise medical billing in the United States as part of the Visualizing Health Policy infographic series, produced in partnership with the Journal of the American Medical Association (JAMA).
9 of 10 Most Commonly Used ARVs in Part D Had List Prices Above Inflation Download…
States are limited in their leverage when it comes to controlling drug spending and use a variety of strategies to manage utilization, including an increased reliance on managed care and pharmacy benefit managers (PBMs). As policymakers debate proposals that include provisions related to Medicaid pharmacy benefits, it is important to understand the challenges state Medicaid programs face and how policy proposals may impact Medicaid beneficiaries and costs.
A new KFF analysis finds that a relatively small share of people with Medicare Advantage or stand-alone Medicare Part D prescription drug coverage voluntarily switch plans during Medicare’s open enrollment period, which runs annually from Oct. 15 to Dec. 7.
This poll examines the issues Democrats most want to hear in the debates, their trust of the Democratic candidates on health care, attitudes towards Medicare-for-all and a public option, perceptions of the Affordable Care Act's health insurance marketplaces, and prospects of legislation to address prescription drug costs.
Drug prices are at the center of health policy debates at both the state and federal levels. . Policymakers are currently debating significant changes to payment for prescription drugs through Medicare and commercial insurers that may also have implications for Medicaid and the Medicaid Prescription Drug Rebate Program (MDRP). This brief explains the MDRP to help policymakers and others understand how Medicaid pays for drugs and any potential consequences of policy changes for the program.
This poll examines health care issues in the Democratic presidential primary , government negotiation of prescription drug prices, party trust on health care, Medicare-for-all, and the pending Texas v. US lawsuit affecting the Affordable Care Act and pre-existing condition protections.
Leading up to the November 2022 midterm elections, abortion access is motivating majorities of Democratic women, women under 50 and and Democratic voters in states with abortion bans. For older voters, some health care issues related to Medicare costs are resonating.
© 2025 KFF